Lyell Q1 FY26 net loss narrows to $24.2 million; revenue slips to $2,000

Lyell Immunopharma, Inc.

Lyell Immunopharma, Inc.

LYEL

0.00
  • Lyell Immunopharma posted a Q1 net loss of USD 24.2 million, narrowing from USD 52.2 million a year earlier, while revenue fell to USD 2,000 from USD 7,000.
  • Research and development expense dropped to USD 36.6 million from USD 43.4 million, while general and administrative expense declined to USD 9.6 million from USD 14 million.
  • Cash, cash equivalents and marketable securities rose to USD 261 million at March 31 from USD 247.2 million at year-end, with runway expected into Q3 2027.
  • PiNACLE pivotal trial of ronde-cel in third-line or later LBCL remains on track for additional data in 2H 2026, with pivotal data expected mid-2027 and BLA submission expected to follow in 2027.
  • PiNACLE-H2H Phase 3 trial in second-line LBCL commenced patient dosing, while the Phase 1 LYL273 study in metastatic colorectal cancer began dosing at Dose Level 3 with a safety update expected in 1H 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lyell Immunopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605061605PRIMZONEFULLFEED9714705) on May 06, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.